1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP

SR One Capital Management LP purchased a new stake in Alumis Inc. (NASDAQ:ALMS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,959,896 shares of the company’s stock, valued at approximately $26,067,000. Alumis comprises approximately 8.2% of SR One Capital Management LP’s holdings, making the stock its 4th largest position. SR One Capital Management LP owned about 4.20% of Alumis as of its most recent SEC filing.

Separately, Towerview LLC acquired a new position in Alumis in the second quarter valued at $4,123,000.

Alumis Stock Performance

ALMS opened at $11.47 on Friday. Alumis Inc. has a 1-year low of $10.37 and a 1-year high of $13.53. The business’s fifty day simple moving average is $12.24.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($21.53). On average, equities research analysts anticipate that Alumis Inc. will post -6.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ALMS. Guggenheim started coverage on Alumis in a research report on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 price objective for the company. Leerink Partners assumed coverage on Alumis in a report on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Monday, August 19th. Leerink Partnrs raised shares of Alumis to a “strong-buy” rating in a research note on Tuesday, July 23rd. Finally, Morgan Stanley assumed coverage on shares of Alumis in a report on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $27.50.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.